<DOC>
	<DOCNO>NCT01135680</DOCNO>
	<brief_summary>Arm 1 : Primary Objective : • To determine safety tolerability multiple ascending , supratherapeutic dos HPN-100 . Arm 2 : Primary Objective : • To assess effect steady-state level HPN-100 metabolite ( 4 phenylbutyric acid [ PBA ] , phenylacetic acid [ PAA ] , phenylacetylglutamine [ PAGN ] ) 12-lead electrocardiogram ( ECG ) parameters healthy male female subject primary endpoint time-matched change baseline QT interval correct heart rate ( HR ) base individual correction method ( QTcI ) .</brief_summary>
	<brief_title>Double-Blind Randomized Crossover Trial Access Electrocardiogram Effects HPN-100</brief_title>
	<detailed_description>Assess effect steady-state level HPN-100 metabolite ( 4-phenylbutryic acid ( PBA ) , phenylacetic acid ( PAA ) , phenylacetylglutamine ( PAGN ) 12-lead electrocardiogram ( ECG ) parameters health male female subject primary endpoint time-matched change baseline QT interval correct heart rate ( HR ) base individual correction method ( QTcl ) .</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Must good health Negative hepatitis panel negative HIV antibody screen Females must nonpregnant , nonlactating , either postmenopausal agree use adequate contraceptive method throughout study Males must either sterile willing use adequate contraceptive method throughout study Willing able comply trial requirement Able comprehend willing sign Informed Consent Form ( ICF ) History clinical manifestation significant allergic , metabolic , hepatic , renal , endocrine , hematological , pulmonary , cardiovascular , gastrointestinal , urological , neurological , psychiatric disorder History hypersensitivity allergy drug compound History stomach intestinal surgery resection History presence abnormal ECG History alcoholism drug addiction within 1 year Use tobaccocontaining nicotinecontaining product within 3 month Participated clinical trial investigational drug ( medical device ) within 30 day Use prescription medications/products contraceptive within 14 day Use overthecounter , nonprescription preparation ( include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation ) within 7 day Test positive drug ( ) abuse , ethanol , cotinine Have donate blood blood component within 30 day Have receive blood product within 2 month Have history unexplained syncope Have family history unexplained sudden death</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>